INTRODUCTION
Cell surface markers, especially immunoglobulin determinants, have been extensively employed as indicators of specific lymphocyte populations, and on the basis of these membrane markers, a number of lymphoproliferative disorders have been classified as "B" or "T" cell derived (1, 2) . By employing immunofluorescence and radiolabeling techniques, peripheral blood cells from human chronic lymphocytic leukemia (CLL)' and cells from other patients with different morphological types of leukemia have been studied for their immunoglobulin surface receptors (3) (4) (5) (6) (7) (8) (9) (10) . Although some reports indicated that the immunoglobulins detected on the cell surface were monoclonal with respect to their light and heavy chain classes (3, 4) , others have supported a polyclonal origin (1, 8) . Studies by Rowe (9) . Fu (13) had recently presented convincing evidence that cytophilic antibodies specific for leukemia-associated antigens common to a morphologic class of leukemia could be found in the serum of leukemic patients. We therefore decided to investigate whether any of the immunoglobulins detectable on leukemic cells had specific antibody activity.
This report describes a cytotoxicity technique which can detect immunoglobulin determinants on the surface of cells of some patients with myeloproliferative and lymphoproliferative disorders. In addition, low pH elution experiments demonstrate that antibodies to leukemia-associated antigens can be detected in eluates of immunoglobulin-bearing cells from some of these patients.
METHODS
Test cells Leukemic patients in this study were considered to be in remission if there were no blast cells present in the peripheral blood or bone marrow by morphological criteria and the peripheral blood cells showed no reactivity for rabbit and nonhuman primate antisera to human leukemia-associated antigens (14) . Leukemic patients studied were in the relapse or untreated stage of their disease and had cells in the peripheral blood which reacted with cytotoxic antisera to human leukemia antigens.
Lymphocytes or leukemic cell suspensions were prepared as follows: 10 ml of heparinized venous blood was mixed with 2.5 ml of Plasmagel (Laboratoire Roger Bellon, Neuilly-Paris, France) and the erythrocytes allowed to sediment at 370C for approximately 20 min. The supernate containing leukocytes, platelets, and some erythrocytes was centrifuged at 1,000 g for 10 min at room temperature and the plasma removed. The buffy coat cells were resuspended in 1 ml of autologous plasma, incubated on washed nylon fiber in a Pasteur pipette at 370C for 20 min, and eluted with 4 (15) . IgE concentrations were determined by a double antibody radioimmunoassay (16) .
Absorption of immutnoglobulin antisera. In order to check the specificity of the anti-heavy chain sera used for cytotoxicity testing, these antisera were absorbed with certain purified immunoglobulin paraproteins. The purity of the absorbing immunoglobulin preparations was confirmed by agar precipitation with known heavy chain-specific antisera and were found to be specific for the designated heavy chain class by this criterion. 10 vol of antisera was mixed with 1 vol of an immunoglobulin preparation (1-2 mg/ml). dilution of K antiserum ranged from 20 to 40% above normal serum controls. When serial dilutions (1: 2, 1: 4, 1: 8) of the various antisera were tested by cytotoxicity with cells from patients with leukemia, lymphoma, or myeloproliferative disease, a variety of positive reaction patterns was observed. Cells from some patients failed to react with any of the antisera or like the cells from some normal donors, reacted only with the K antiserum. However, cells from some leukemic patients reacted with one or more antisera to heavy chain determinants as well as with antisera to K-and/or X-light chain determinants. The percentage of cells killed varied from 20% increase over normal serum controls to 90% total lysis, and the titers ranged from 1: 2 to 1: 8 or greater. Since the erythrocyte-absorbed antisera were often slightly anticomplementary at a 1: 1 dilution, the lowest dilution routinely tested was 1: 2. Table II shows the cytotoxicity titers and percentage of cells lysed from four of the reactive CLL and acute myelomonocytic leukemia (AMML) patients. These examples were chosen to show two patterns of reactivity. In one type, cells from patients C.L.E. and C.L.A. reacted only with the antisera to K-light chain and one heavy chain determinant, suggesting a possible monoclonal origin of the surface immunoglobulin. In the other, cells from patients B. U. and H. A. reacted with several antisera to light and heavy chain determinants, suggesting a polyclonal distribution of immunoglobulins on the membrane. Cells from all reactive leukemic patients diagnosed as AML, acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), and myelofibrosis gave reaction patterns which suggested a polyclonal origin of the immunoglobulins. Reactions of selected patients in these categories are shown in Table  III . Cells from remission patients in all leukemia categories and patients with Hodgkins' disease, lymphoma, or polycythemia vera failed to react with the antiserum to X-light chains and antisera to all heavy chain determinants.
Absorption studies. The goat antisera to human immunoglobulin heavy chain determinants were absorbed with purified immunoglobulins in order to determine whether the cytotoxic activity of the antisera could be correlated with the immunoglobulin class specificity. The antisera were absorbed as described in Methods and then tested by cytotoxicity with cells from patients who were reactive with the unabsorbed antisera. The absorbed antisera were also tested by immunodiffusion with the purified immunoglobulin preparations. In all instances absorption of a heavy chain antiserum with a specific immunoglobulin class removed the precipitin line for that class whereas absorption with other immunoglobulin classes, as expected, did not alter the agar precipitation reactivity of the antiserum. The cytotoxic activity of the immunoglobulin antisera to heavy chain class determinants was abolished by absorption with the specific immunoglobulin used to define the antisera by precipitation (Table IV) .
Effect of trypsin. Previous studies from our laboratory (14, 17) demonstrated that treatment of human leukemic cells with trypsin resulted in a loss followed by a regeneration of leukemia-associated antigens de- Elution studies.
Since we could not demonstrate regeneration of the heavy chain sites and since these sites could not be detected on significant numbers of normal cells or cells from remission patients, we felt that they might represent antibodies absorbed in vivo to leukemic cell surface antigens. Therefore, low pH (3.2) eluates were prepared from some patients' cells which had been reactive with antisera to heavy chain determinants. Serum from these patients at the time the cells were studied for elution did not have detectable antibodies to human leukemia-associated antigens. Information on the cell donors and the eluates studied is given in Table VII. All of the eluates studied had immunoglobulins detectable by immunodiffusion or radioimmunoassay.
Eluates from the cells of three CML patients studied had particularly high levels (>100 mg/100 ml) of IgM.
The eluates were then tested by cytotoxicity for antibodies to leukemia and normal cell-associated antigens. The results of these studies are given in Table VIII Eluates from the peripheral blood cells of the three CML patients studied had good cytotoxic activity especially for cells from patients with myeloid leukemia or myelofibrosis. Occasional reactions with cells from normal donors or patients with CLL were also noted; however, the reactions were low titered (1: 1 or 1: 2), and less than 50% of the cells were lysed. The reactive eluates always gave a greater percentage of lysis and were higher titered when tested with leukemic cells of (20) reported complement-dependent cytolysis of human B lymphocytes by an antisera to human immunoglobulin light chains. The data of these workers on the percentage of normal blood lymphocytes reacting with light chain antisera is similar to the percentage of cells lysed by our anti-K serum (10-30%). There are, however, numerous technical problems with using the microcytotoxicity assay to reliably detect specific cell cytolysis in the 5-20% range. This is because of the variability in the background lysis with rabbit complement and normal goat or rabbit serum controls and the method used to prepare the lymphocytes. Nevertheless, when the percentage of cells bearing detectable immunoglobulin determinants are above these ranges (e. g., tonsillar lymphocytes or cells from leukemic patients) the microcytotoxicity test provides a relatively simple and rapid technique for detecting cell surface immunoglobulin determinants.
The reactivity of several heavy chain antisera with leukemia cells from the same donor indicated a polyclonal distribution and suggested that if surface immunoglobulins were being detected they may be present on the cell membrane as a result of in vivo sensitization or that the immunoglobulin antisera were detecting other antigens by cytotoxicity. The data presented in Table IV show that the cytotoxicity reactions are related to the immunoglobulin specificity of the commercial antisera as defined by agar precipitation. The loss of reactivity of the immunoglobulin antisera with trypsinized target cells and the failure of the cells to regenerate antigenic reactivity with the antisera to X-light chain-and heavy chain-specific determinants (Table V However, some of the eluates were capable of lysing cells from other patients and, in the case of the eluates from the CLL patient, autologous cells at a later date with both human and rabbit complement. If the in vitro cytotoxic activity of the eluates were due only to IgG, then one could argue that in vivo antibodies in the serum of patients in the relapse or untreated stage are in such extreme cell excess and that there would be only a remote chance of two IgG molecules being situated close enough on the cell membrane to trigger the complement sequence. If the cytotoxic antibody activity of the eluates from the CML patients is shown by column chromatography or gradient centrifugation to be related to IgM then this argument would not be valid and interference or blocking by non-complement-fixing antibodies on the target cell would be a more logical explanation for the failure to get in vivo lysis.
Eluates from leukemic cells could represent valuable diagnostic and prognostic reagents for detecting and studying human leukemia-associated antigens. Large numbers of cells from patients subjected to plasmapheresis could provide reasonable quantities of eluates for this purpose. The eluates have a distinct advantage over heteroantisera for the detection of leukemia-associated antigens (14, 17) in that they do not require extensive absorption with normal cells. The few reactions noted between the eluates and cells from normal donors or patients with different histological types of leukemia may be nonspecific and might be eliminated by Sephadex fractionation of the eluates.
